For investors in these low-cost, autopilot portfolios that dispense with stock pickers and passively replicate the holdings of a broad basket of stocks or bonds, thebestisyettobe.
The new drug isthebest evidence yet that biotech companies are likely tobe drawn into the fight against bioterror, thanks to stripped-down U.S. regulations that make it easier to get drugs approved to treat diseases like anthrax and smallpox.